The Firm is representing Capsugel S.A. (“Capsugel”), a portfolio company of KKR, in connection with the acquisition of Capsugel by Lonza Group AG (“Lonza”) (VTX: LONN.VX) for $5.5 billion, including refinancing of approximately $2 billion of existing Capsugel debt. The transaction is expected to close in mid-2017 and is subject to certain regulatory approvals and other customary closing conditions.
Capsugel designs, develops and manufactures a wide range of innovative dosage forms for the biopharmaceutical and consumer health and nutrition industries. Headquartered in Morristown, N.J., Capsugel has approximately 3,600 employees and 13 facilities on three continents. Capsugel was acquired by KKR in a 2011 carve-out acquisition from Pfizer.
Lonza is one of the world’s leading suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza has a market capitalization of approximately $8.8 Billion and approximately 9,800 employees worldwide and is headquartered in Basel, Switzerland.
The Simpson Thacher team includes Mark Pflug, Jakob Rendtorff, Matthew Rogers, Matthew Schwartz, Meredith Hunt, Alexander Cushman and Jake Phillips (M&A, New York); Clare Gaskell (M&A, London); Nancy Mehlman, Taylor Weinstein and Morgan Otway (Tax); David Rubinsky, Jennifer Pepin and Monisha Bhayana (Executive Compensation and Employee Benefits); James Cross (Credit); Richard Fenyes, Brian Rosenzweig and Benjamin Heriaud (Capital Markets); Peter Guryan, Ellen Frye and Richard Jamgochian (Antitrust); Lori Lesser and Linda Nyberg (Intellectual Property); Krista McManus and Dennis Loiacono (Real Estate); Adeeb Fadil and Noreen Lavan (Environmental); and Joyce Xu and Andrew Des Rault (Derivatives).